CCR2 and coronary artery disease: a woscops substudy
1 GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, UK
2 Robertson Centre for Biostatistics, Boyd Orr Building, University of Glasgow, G12 8QQ, UK
3 Division of Medical Sciences, University of Glasgow, Western Infirmary, Glasgow, G11 6NT, UK
4 Current Address: Takeda Singapore, 10 Biopolis Road, 03-01/02 Chromas, 138670, Singapore
BMC Research Notes 2010, 3:31 doi:10.1186/1756-0500-3-31Published: 2 February 2010
Several lines of evidence support a role for CCL2 (monocyte chemotactic protein-1) and its receptor CCR2 in the development of atherosclerosis. The aim of the present study was to determine the association of the CCR2 Val64Ile polymorphism with the development of coronary artery disease in the WOSCOPS study sample set.
A total of 443 cases and 1003 controls from the West of Scotland Coronary Prevention Study (WOSCOPS) were genotyped for the Val64Ile polymorphism in the CCR2 gene. Genotype frequencies were compared between cases and controls. The CCR2 Val64Ile polymorphism was found not to be associated with coronary events in this study population (odds ratio 1.15, 95% CI 0.82-1.61, p = 0.41).
This case-control study does not support an association of the CCR2 Val64Ile polymorphism with coronary artery disease in the WOSCOPS sample set and does not confirm a possible protective role for CCR2 Val64Ile in the development of coronary artery disease.